These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26457932)

  • 1. Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests.
    Soria A; Barbaud A; Assier H; Avenel-Audran M; Tétart F; Raison-Peyron N; Amarger S; Girardin P; Francès C;
    Dermatology; 2015; 231(4):353-9. PubMed ID: 26457932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study.
    Chasset F; Arnaud L; Jachiet M; Monfort JB; Bouaziz JD; Cordoliani F; Bagot M; Barbaud A; Francès C
    J Am Acad Dermatol; 2018 Jan; 78(1):107-114.e1. PubMed ID: 29061479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
    Mittal L; Zhang L; Feng R; Werth VP
    J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Antimalarial Therapy in Patients Who Are Hypersensitive to Hydroxychloroquine.
    Riley K; Schwager Z; Stern M; Vleugels RA; Femia A
    JAMA Dermatol; 2019 Apr; 155(4):491-493. PubMed ID: 30758479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous adverse drug reaction to oral acetazolamide and skin tests.
    Jachiet M; Bellon N; Assier H; Amsler E; Gaouar H; Pecquet C; Bourrain JL; Bégon E; Chosidow O; Francès C; Ingen-Housz-Oro S; Soria A
    Dermatology; 2013; 226(4):347-52. PubMed ID: 23817276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study.
    Kobak S; Deveci H
    Int J Rheum Dis; 2010 Aug; 13(3):e11-5. PubMed ID: 20704603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug skin tests in cutaneous adverse drug reactions to pristinamycin: 29 cases with a study of cross-reactions between synergistins.
    Barbaud A; Trechot P; Weber-Muller F; Ulrich G; Commun N; Schmutz JL
    Contact Dermatitis; 2004 Jan; 50(1):22-6. PubMed ID: 15059099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Eye toxicity of antimalarial agents].
    Graña Gil J; Cabana Vázquez M; Vázquez González A; Sánchez Meizoso MO
    An Med Interna; 2002 Apr; 19(4):189-91. PubMed ID: 12090061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions.
    Barbaud A; Gonçalo M; Bruynzeel D; Bircher A;
    Contact Dermatitis; 2001 Dec; 45(6):321-8. PubMed ID: 11846746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse cutaneous drug reactions with antimalarials in cutaneous lupus and dermatomyositis: A retrospective cohort study.
    Gonzalez CD; Hansen C; Clarke JT
    J Am Acad Dermatol; 2019 Sep; 81(3):859-860. PubMed ID: 31085265
    [No Abstract]   [Full Text] [Related]  

  • 11. Isolated hyperpigmentation of the oral mucosa due to hydroxychloroquine.
    Kalampalikis A; Goetze S; Elsner P
    J Dtsch Dermatol Ges; 2012 Dec; 10(12):921-2. PubMed ID: 23190463
    [No Abstract]   [Full Text] [Related]  

  • 12. Negative predictive value of drug skin tests in investigating cutaneous adverse drug reactions.
    Waton J; Tréchot P; Loss-Ayav C; Schmutz JL; Barbaud A
    Br J Dermatol; 2009 Apr; 160(4):786-94. PubMed ID: 19120340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimalarial drug induced decrease in creatinine clearance.
    Landewé RB; Vergouwen MS; Goeei The SG; Van Rijthoven AW; Breedveld FC; Dijkmans BA
    J Rheumatol; 1995 Jan; 22(1):34-7. PubMed ID: 7699677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term use of antimalarial drugs in rheumatic diseases.
    Jover JA; Leon L; Pato E; Loza E; Rosales Z; Matias MA; Mendez-Fernandez R; Díaz-Valle D; Benitez-Del-Castillo JM; Abasolo L
    Clin Exp Rheumatol; 2012; 30(3):380-7. PubMed ID: 22339928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal use of antimalarials in treating cutaneous lupus erythematosus.
    Wozniacka A; McCauliffe DP
    Am J Clin Dermatol; 2005; 6(1):1-11. PubMed ID: 15675885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
    Choon SE; Lai NM
    Indian J Dermatol Venereol Leprol; 2012; 78(6):734-9. PubMed ID: 23075643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study.
    Ang GC; Werth VP
    Arch Dermatol; 2005 Jul; 141(7):855-9. PubMed ID: 16027300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type IV allergy to antimalarials can mimic cutaneous manifestations of lupus erythematosus.
    Borik L; Petzelbauer P; Quint T; Wöhrl S; Kinaciyan T; Heil PM
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):e94-e96. PubMed ID: 30223310
    [No Abstract]   [Full Text] [Related]  

  • 20. The usefulness of skin tests to prove drug hypersensitivity.
    Lammintausta K; Kortekangas-Savolainen O
    Br J Dermatol; 2005 May; 152(5):968-74. PubMed ID: 15888154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.